Pfizer TUKYSA FDA Approval: Chemotherapy-Free Front-Line Maintenance Now Available for HER2+ Metastatic Breast Cancer
The FDA has approved Tecentriq and Tecentriq Hybreza with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III dMMR colon cancer, based on the phase III ATOMIC trial.
